Pharma & Life Sciences

GPC3 CAR T cells, IL-15, IL-21, ATRT, CNS rhabdoid tumors, Baylor

GPC3 CAR T cells, IL-15, IL-21, ATRT, CNS rhabdoid tumors, Baylor

Nebulized Stem Cell EVs for Idiopathic Pulmonary Fibrosis

ClinicalTrials.gov registered a new Phase I study (NCT07515066) investigating nebulized stem cell extracellular vesicles (EVs) for treatment of idiopathic pulmonary fibrosis. The trial is listed as not yet recruiting and will evaluate safety and tolerability of the inhaled stem cell EV therapy.

Adaptive proton therapy pediatric solid tumors Hodgkin's lymphoma

ClinicalTrials.gov registered a new Phase 2 interventional study (NCT07514819) evaluating adaptive proton therapy for pediatric patients with solid tumors and Hodgkin's lymphoma. The single-arm trial will assess treatment response rates, survival outcomes, and treatment-related toxicity in pediatric oncology patients. The study is sponsored by the University of Pennsylvania and will enroll approximately 40 participants.

MR-guided adaptive stereotactic radiotherapy for endometrial cancer, Radboud University

The National Library of Medicine registered a new clinical trial (NCT07514325) on ClinicalTrials.gov studying MR-guided adaptive stereotactic radiotherapy for endometrial cancer. The single-arm study will enroll an estimated 20 participants at Radboud University Medical Center in the Netherlands to evaluate feasibility and toxicity outcomes of adaptive radiotherapy guided by MRI imaging.

Pre-dementia study, MCI, Alzheimer, APOE-4, recruiting

The National Library of Medicine registered a new clinical trial on ClinicalTrials.gov (NCT07516119) studying pre-dementia and mild cognitive impairment in participants with Alzheimer's disease and APOE-4 genetic markers. The study is currently recruiting participants. ClinicalTrials.gov serves as the federal registry for clinical trials required under FDAAA 801.

QL1706 bispecific antibody neoadjuvant trial, not recruiting

The National Library of Medicine updated ClinicalTrials.gov trial record NCT07515469 for QL1706, a bispecific antibody, to reflect a change in recruitment status from recruiting to not recruiting in a neoadjuvant treatment setting. The trial, which evaluates QL1706 as a bispecific antibody therapeutic, has modified its enrollment status. No specific enrollment numbers or timeline changes were provided in the status update.

CMS FY 2027 IPF proposed rule, comment deadline June 1

CMS FY 2027 IPF proposed rule, comment deadline June 1

Movement of Plants and Plant Products from Hawaii and the Territories - Information Collection Extension

APHIS is requesting public comment on a revision to and extension of approval for information collection associated with regulations for interstate movement of fruits and vegetables from Hawaii and the Territories. The collection covers activities including limited permits, inspections, transit permits, compliance agreements, certification, and recordkeeping under OMB Control Number 0579-0346. Comments are due by June 8, 2026.

CMS Finalizes 2027 Medicare Advantage and Part D Payment Policies

CMS released the Calendar Year 2027 Medicare Advantage and Part D Rate Announcement, finalizing payment policies projected to result in a net average increase of 2.48%, representing over $13 billion in additional MA payments. The finalized policies address coding differentials between MA and Original Medicare and establish three guiding principles for risk adjustment: simplicity, competition, and payment accuracy.

2027 Medicare Advantage and Part D Rate Announcement

CMS released the CY 2027 Medicare Advantage and Part D Rate Announcement, finalizing capitation rates and payment policies. The final policies result in a 2.48% average payment increase, representing over $13 billion in additional payments to Medicare Advantage plans. The announcement includes risk model revisions, Star Ratings changes, and updated normalization factors affecting plan payment calculations.